Stevanato Group S.p.A. (NYSE:STVN) Given Average Recommendation of “Buy” by Analysts

Stevanato Group S.p.A. (NYSE:STVN) has received a consensus rating of “Buy” from the six analysts that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and two have issued a strong buy rating on the company.

STVN has been the subject of several research analyst reports. Wolfe Research started coverage on Stevanato Group in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $21.00 price objective for the company. Weiss Ratings upgraded Stevanato Group from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 16th. Finally, TD Cowen raised Stevanato Group to a “strong-buy” rating in a report on Wednesday, June 17th.

Stevanato Group Price Performance

STVN stock opened at €21.13 on Wednesday. The firm has a 50 day moving average of €19.04 and a 200-day moving average of €17.06. The company has a market cap of $6.40 billion, a price-to-earnings ratio of 37.73, a PEG ratio of 1.73 and a beta of 0.77. The company has a current ratio of 1.61, a quick ratio of 1.08 and a debt-to-equity ratio of 0.21. Stevanato Group has a 12-month low of €12.89 and a 12-month high of €28.00.

Insiders Place Their Bets

In other Stevanato Group news, CFO Lago Marco Dal sold 4,209 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of €20.09, for a total transaction of €84,558.81. Following the completion of the transaction, the chief financial officer directly owned 81,144 shares in the company, valued at approximately €1,630,182.96. This trade represents a 4.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Elisabetta Magistretti sold 2,045 shares of Stevanato Group stock in a transaction dated Friday, August 7th. The stock was sold at an average price of €20.09, for a total transaction of €41,084.05. Following the transaction, the director owned 2,930 shares of the company’s stock, valued at approximately €58,863.70. The trade was a 41.11% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 14,249 shares of company stock worth $268,346.

Institutional Trading of Stevanato Group

Several large investors have recently modified their holdings of STVN. GW&K Investment Management LLC increased its stake in shares of Stevanato Group by 76.2% during the 4th quarter. GW&K Investment Management LLC now owns 2,440 shares of the company’s stock worth $49,000 after purchasing an additional 1,055 shares in the last quarter. Fifth Third Bancorp lifted its stake in Stevanato Group by 22.6% in the 1st quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock valued at $58,000 after buying an additional 773 shares in the last quarter. State of Wyoming lifted its stake in Stevanato Group by 39,216.7% in the 2nd quarter. State of Wyoming now owns 2,359 shares of the company’s stock valued at $58,000 after buying an additional 2,353 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Stevanato Group during the 3rd quarter valued at $68,000. Finally, Tower Research Capital LLC TRC grew its holdings in Stevanato Group by 1,268.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,585 shares of the company’s stock valued at $112,000 after buying an additional 4,250 shares during the last quarter.

About Stevanato Group

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.